Physician profile
Lily Tran
NPI 1366494874
$11,520.93
in general payments reported to CMS, 2019-2025
34 companies · $2,544 in 2025
The $2,544 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $716 · 2021: $1,607 · 2022: $1,936 · 2023: $1,862 · 2024: $1,967 · 2025: $2,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,373.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,955.76 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,775.10 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $618.45 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $602.03 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $475.23 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $435.82 | 2019-2025 | Livdelzi |
| Nestle Healthcare Nutrition INC. | $416.27 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $409.18 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $366.69 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $267.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $224.62 | 2020-2024 | Linzess |
| Ardelyx, INC. | $179.91 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $178.43 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Evoke Pharma, INC. | $173.21 | 2021-2024 | Gimoti |
| Organon LLC | $159.11 | 2023-2025 | Hadlima, Renflexis |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $139.29 | 2021-2025 | Pancreaze |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.99 | 2023-2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $130.72 | 2023-2025 | Ocaliva |
| Smith+Nephew, INC. | $124.12 | 2023 | Pico, Grafix Pl |
| Astrazeneca Pharmaceuticals LP | $112.67 | 2023 | Breztri |
| Allergan, INC. | $111.92 | 2019 | |
| Merck Sharp & Dohme LLC | $81.83 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $76.47 | 2022-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $75.20 | 2022 | |
| Enterra Medical, INC. | $52.70 | 2024-2025 | |
| Novo Nordisk INC | $51.96 | 2025 | Wegovy |
| Medtronic, INC. | $50.27 | 2022-2025 | Pillcam, Gi Genius |
| Daiichi Sankyo INC. | $24.95 | 2021 | |
| Echosens North America, INC. | $24.46 | 2022-2023 | Fibroscan |
| Lilly USA, LLC | $21.49 | 2025 | Omvoh |
| Exact Sciences Corporation | $19.07 | 2024 | Cologuard Collection Kit |
| Innovation Technologies INC | $17.78 | 2025 | Irrisept |
| Ipsen Biopharmaceuticals, INC | $17.04 | 2025 | Iqirvo |
| Mauna Kea Technologies, INC. | $16.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.